II 

116TH CONGRESS 

1ST SESSION S. 378 

To amend the Internal Revenue Code of 1986 to establish an excise tax 

on certain prescription drugs which have been subject to a price spike, 

and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

FEBRUARY 7, 2019 

Mr. BROWN (for himself, Mrs. GILLIBRAND, and Ms. HASSAN) introduced the 

following bill; which was read twice and referred to the Committee on Finance 

A BILL 

To amend the Internal Revenue Code of 1986 to establish 

an excise tax on certain prescription drugs which have 

been subject to a price spike, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Stop Price Gouging 

5 Act’’. 

6 SEC. 2. IDENTIFICATION OF PRESCRIPTION DRUG PRICE 

7 SPIKES. 

8 (a) DEFINITIONS.—In this section: 


kjohnson on DSK79L0C42 with BILLS
2 

•S 378 IS

1 (1) APPLICABLE ENTITY.—The term ‘‘applica2 ble entity’’ means the holder of an application ap3 proved under subsection (c) or (j) of section 505 of 

4 the Federal Food, Drug, and Cosmetic Act (21 

5 U.S.C. 355) or of a license issued under subsection 

6 (a) or (k) of section 351 of the Public Health Serv7 ice Act (42 U.S.C. 262) for a drug described in 

8 paragraph (5)(A). 

9 (2) AVERAGE MANUFACTURER PRICE.—The 

10 term ‘‘average manufacturer price’’— 

11 (A) has the same meaning given such term 

12 under section 1927(k)(1) of the Social Security 

13 Act (42 U.S.C. 1396r–8(k)(1)); or 

14 (B) with respect to a drug for which there 

15 is no average manufacturer price as so defined, 

16 such term shall mean the wholesale acquisition 

17 cost of the drug. 

18 (3) COMMERCE.—The term ‘‘commerce’’ has 

19 the meaning given such term in section 4 of the 

20 Federal Trade Commission Act (15 U.S.C. 44). 

21 (4) INSPECTOR GENERAL.—The term ‘‘Inspec22 tor General’’ means the Inspector General of the De23 partment of Health and Human Services. 

24 (5) PRESCRIPTION DRUG.— 


kjohnson on DSK79L0C42 with BILLS
3 

•S 378 IS

1 (A) IN GENERAL.—The term ‘‘prescription 

2 drug’’ means any drug (as defined in section 

3 201(g) of the Federal Food, Drug, and Cos4 metic Act (21 U.S.C. 321(g))), including a com5 bination product whose primary mode of action 

6 is determined under section 503(g) of such Act 

7 (21 U.S.C. 353(g)) to be that of a drug, and 

8 that— 

9 (i) is subject to section 503(b)(1) of 

10 the Federal Food, Drug, and Cosmetic Act 

11 (21 U.S.C. 353(b)(1)); and 

12 (ii) is covered by a Federal health 

13 care program (as defined in section 

14 1128B(f) of the Social Security Act (42 

15 U.S.C. 1320a–7b(f))). 

16 (B) TREATMENT OF REFORMULATED

17 DRUGS.—For purposes of this section, a pre18 scription drug with respect to which the Sec19 retary of Health and Human Services has ap20 proved any minor reformulation that does not 

21 produce a meaningful therapeutic benefit, the 

22 drug that was approved prior to any such refor23 mulation and the drug with any such reformu24 lation shall be considered one prescription drug. 

25 (6) PRICE SPIKE.— 


kjohnson on DSK79L0C42 with BILLS
4 

•S 378 IS

1 (A) IN GENERAL.—The term ‘‘price spike’’ 

2 means an increase in the average manufacturer 

3 price in commerce of a prescription drug for 

4 which the price spike percentage is equal to or 

5 greater than applicable price increase allowance. 

6 (B) PRICE SPIKE PERCENTAGE.—The 

7 price spike percentage is the percentage (if any) 

8 by which— 

9 (i) the average manufacturer price of 

10 a prescription drug in commerce for the 

11 calendar year; exceeds 

12 (ii) the average manufacturer price of 

13 such prescription drug in commerce for the 

14 calendar year preceding such year. 

15 (C) APPLICABLE PRICE INCREASE ALLOW16 ANCE.—The applicable price increase allowance 

17 for any calendar year is the percentage (round18 ed to the nearest one-tenth of 1 percent) by 

19 which the C-CPI-U (as defined in section 

20 1(f)(6) of the Internal Revenue Code of 1986) 

21 for that year exceeds the C-CPI-U for the pre22 ceding calendar year. 

23 (7) PRICE SPIKE REVENUE.— 

24 (A) IN GENERAL.—The price spike revenue 

25 for any calendar year is an amount equal to— 


kjohnson on DSK79L0C42 with BILLS
5 

•S 378 IS

1 (i) the gross price spike revenue, 

2 minus 

3 (ii) the adjustment amount. 

4 (B) GROSS PRICE SPIKE REVENUE.—The 

5 gross price spike revenue for any calendar year 

6 is an amount equal to the product of— 

7 (i) an amount equal to the difference 

8 between clause (i) of paragraph (6)(B) and 

9 clause (ii) of such paragraph; and 

10 (ii) the total number of units of the 

11 prescription drug which were sold in com12 merce in such calendar year. 

13 (C) ADJUSTMENT AMOUNT.—The adjust14 ment amount is the amount, if any, of the gross 

15 price spike revenue which the Inspector General 

16 has determined is due solely to an increase in 

17 the cost of the inputs necessary to manufacture 

18 the prescription drug subject to the price spike. 

19 (b) SUBMISSION BY PHARMACEUTICAL COMPANIES

20 OF INFORMATION TO INSPECTOR GENERAL.— 

21 (1) IN GENERAL.—For each prescription drug, 

22 the applicable entity shall submit to the Inspector 

23 General a quarterly report that includes the fol24 lowing: 


kjohnson on DSK79L0C42 with BILLS
6 

•S 378 IS

1 (A) For each prescription drug of the ap2 plicable entity— 

3 (i) the total number of units of the 

4 prescription drug which were sold in com5 merce in the preceding calendar quarter; 

6 (ii) the average and median price per 

7 unit of such prescription drug in commerce 

8 in the preceding calendar quarter, disag9 gregated by month; and 

10 (iii) the gross revenues from sales of 

11 such prescription drug in commerce in the 

12 preceding calendar quarter. 

13 (B) Such information related to increased 

14 input costs or public health considerations as 

15 the applicable entity may wish the Inspector 

16 General to consider in making a determination 

17 under clause (ii) of subsection (c)(2)(B) or an 

18 assessment in clause (iii) of such subsection for 

19 the preceding calendar quarter. 

20 (C) Such information related to any antici21 pated increased input costs for the subsequent 

22 calendar quarter as the applicable entity may 

23 wish the Inspector General to consider in mak24 ing a determination under clause (ii) of sub25 section (c)(2)(B) or an assessment in clause 


kjohnson on DSK79L0C42 with BILLS
7 

•S 378 IS

1 (iii) of such subsection for such calendar quar2 ter. 

3 (2) PENALTY FOR FAILURE TO SUBMIT.— 

4 (A) IN GENERAL.—An applicable entity de5 scribed in paragraph (1) that fails to submit in6 formation to the Inspector General regarding a 

7 prescription drug, as required by such para8 graph, before the date specified in paragraph 

9 (3) shall be liable for a civil penalty, as deter10 mined under subparagraph (B). 

11 (B) AMOUNT OF PENALTY.—The amount 

12 of the civil penalty shall be equal to the product 

13 of— 

14 (i) an amount, as determined appro15 priate by the Inspector General, which is— 

16 (I) not less than 0.5 percent of 

17 the gross revenues from sales of the 

18 prescription drug described in sub19 paragraph (A) for the preceding cal20 endar year, and 

21 (II) not greater than 1 percent of 

22 the gross revenues from sales of such 

23 prescription drug for the preceding 

24 calendar year, and 


kjohnson on DSK79L0C42 with BILLS
8 

•S 378 IS

1 (ii) the number of days in the period 

2 between— 

3 (I) the applicable date specified 

4 in paragraph (3), and 

5 (II) the date on which the In6 spector General receives the informa7 tion described in paragraph (1) from 

8 the applicable entity. 

9 (3) SUBMISSION DEADLINE.—An applicable en10 tity shall submit each quarterly report described in 

11 paragraph (1) not later than January 17, April 18, 

12 June 15, and September 15 of each calendar year. 

13 (c) ASSESSMENT BY INSPECTOR GENERAL.— 

14 (1) IN GENERAL.—Not later than the last day 

15 in February of each year, the Inspector General, in 

16 consultation with other relevant Federal agencies 

17 (including the Federal Trade Commission), shall— 

18 (A) complete an assessment of the infor19 mation the Inspector General received pursuant 

20 to subsection (b)(1) with respect to sales of pre21 scription drugs in the preceding calendar year; 

22 and 

23 (B) in the case of any prescription drug 

24 which satisfies the conditions described in para25 graph (1) or (2) of subsection (d), submit a recVerDate Sep 11 2014 03:17 Feb 16, 2019 Jkt 089200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\S378.IS S378

kjohnson on DSK79L0C42 with BILLS
9 

•S 378 IS

1 ommendation to the Secretary of Health and 

2 Human Services that such drug be exempted 

3 from application of the tax imposed under sec4 tion 4192 of the Internal Revenue Code of 1986 

5 (as added by section 3 of this Act) for such 

6 year. 

7 (2) ELEMENTS.—The assessment required by 

8 paragraph (1)(A) shall include the following: 

9 (A) Identification of each price spike relat10 ing to a prescription drug in the preceding cal11 endar year. 

12 (B) For each price spike identified under 

13 subparagraph (A)— 

14 (i) a determination of the price spike 

15 revenue; 

16 (ii) a determination regarding the ac17 curacy of the information submitted by the 

18 applicable entity regarding increased input 

19 costs; and 

20 (iii) an assessment of the rationale of 

21 the applicable entity for the price spike. 

22 (d) EXEMPTION OF CERTAIN DRUGS.— 

23 (1) IN GENERAL.—The Secretary of Health and 

24 Human Services, upon recommendation of the In25 spector General pursuant to subsection (c)(1)(B), 


kjohnson on DSK79L0C42 with BILLS
10 

•S 378 IS

1 may exempt any prescription drug which has been 

2 subject to a price spike during the preceding cal3 endar year from application of the tax imposed 

4 under section 4192 of the Internal Revenue Code of 

5 1986 for such year, if the Secretary determines 

6 that— 

7 (A) based on information submitted pursu8 ant to subsection (b)(1)(B), a for-cause price 

9 increase exemption should apply; or 

10 (B)(i) the prescription drug which has 

11 been subject to a price spike has an average 

12 manufacturer price of not greater than $10 for 

13 a 30 day supply; and 

14 (ii) such drug is marketed by not less than 

15 3 other holders of applications approved under 

16 subsection (c) or (j) of section 505 of the Fed17 eral Food, Drug, and Cosmetic Act (21 U.S.C. 

18 355), where such applications approved under 

19 such subsection (j) use as a reference drug the 

20 drug so approved under such subsection (c). 

21 (2) CLARIFICATION.—In considering, under 

22 paragraph (1)(A), information submitted pursuant 

23 to subsection (b)(1)(B), the Secretary— 


kjohnson on DSK79L0C42 with BILLS
11 

•S 378 IS

1 (A) has the discretion to determine that 

2 such information does not warrant a for-cause 

3 price increase exemption; and 

4 (B) shall exclude from such consideration 

5 any information submitted by the applicable en6 tity threatening to curtail or limit production of 

7 the prescription drug if the Secretary does not 

8 grant an exemption from the application of the 

9 tax under section 4192 of the Internal Revenue 

10 Code of 1986. 

11 (e) INSPECTOR GENERAL REPORT TO INTERNAL

12 REVENUE SERVICE.— 

13 (1) IN GENERAL.—Subject to paragraph (3), 

14 not later than the last day in February of each year, 

15 the Inspector General shall transmit to the Internal 

16 Revenue Service a report on the findings of the In17 spector General with respect to the information the 

18 Inspector General received under subsection (b)(1) 

19 with respect to the preceding calendar year and the 

20 assessment carried out by the Inspector General 

21 under subsection (c)(1)(A) with respect to such in22 formation. 

23 (2) CONTENTS.—The report transmitted under 

24 paragraph (1) shall include the following: 


kjohnson on DSK79L0C42 with BILLS
12 

•S 378 IS

1 (A) The information received under sub2 section (b)(1) with respect to the preceding cal3 endar year. 

4 (B) The price spikes identified under sub5 paragraph (A) of subsection (c)(2). 

6 (C) The price spike revenue determinations 

7 made under subparagraph (B)(i) of such sub8 section. 

9 (D) The determinations and assessments 

10 made under clauses (ii) and (iii) of subpara11 graph (B) of such subsection. 

12 (3) NOTICE AND OPPORTUNITY FOR HEAR13 ING.— 

14 (A) IN GENERAL.—No report shall be 

15 transmitted to the Internal Revenue Service 

16 under paragraph (1) in regards to a prescrip17 tion drug unless the Inspector General has pro18 vided the applicable entity with— 

19 (i) the assessment of such drug under 

20 subsection (c)(1)(A); and 

21 (ii) notice of their right to a hearing 

22 in regards to such assessment. 

23 (B) NOTICE.—The notice required under 

24 subparagraph (A) shall be provided to the ap25 plicable entity not later than 30 days after comVerDate Sep 11 2014 03:17 Feb 16, 2019 Jkt 089200 PO 00000 Frm 00012 Fmt 6652 Sfmt 6201 E:\BILLS\S378.IS S378

kjohnson on DSK79L0C42 with BILLS
13 

•S 378 IS

1 pletion of the assessment under subsection 

2 (c)(1)(A). 

3 (C) REQUEST FOR HEARING.—Subject to 

4 subparagraph (E), an applicable entity may re5 quest a hearing before the Secretary of Health 

6 and Human Services not later than 30 days 

7 after the date on which the notice under sub8 paragraph (B) is received. 

9 (D) COMPLETION OF HEARING.—In the 

10 case of an applicable entity which requests a 

11 hearing pursuant to subparagraph (C), the Sec12 retary of Health and Human Services shall, not 

13 later than 12 months after the date on which 

14 the assessment under subsection (c)(1)(A) was 

15 completed by the Inspector General— 

16 (i) make a final determination in re17 gards the accuracy of such assessment; 

18 and 

19 (ii) provide the report described in 

20 paragraph (2) to the Internal Revenue 

21 Service. 

22 (E) LIMITATION.—An applicable entity 

23 may request a hearing under subparagraph (C) 

24 with respect to a particular prescription drug 

25 only once within a 5-year period. 


kjohnson on DSK79L0C42 with BILLS
14 

•S 378 IS

1 (4) PUBLICATION.— 

2 (A) IN GENERAL.—Not later than the last 

3 day in February of each year, subject to sub4 paragraph (B), the Inspector General shall 

5 make the report transmitted under paragraph 

6 (1) available to the public, including on the 

7 Internet website of the Inspector General, sub8 ject to subparagraph (B). 

9 (B) PROPRIETARY INFORMATION.—The 

10 Inspector General shall ensure that any infor11 mation made public in accordance with sub12 paragraph (A) excludes trade secrets and con13 fidential commercial information. 

14 (f) NOTIFICATION.—The Secretary of the Treasury, 

15 in conjunction with the Inspector General, shall notify, at 

16 such time and in such manner as the Secretary of the 

17 Treasury shall provide, each applicable entity in regard 

18 to any prescription drug which has been determined to 

19 have been subject to a price spike during the preceding 

20 calendar year and the amount of the tax imposed on such 

21 applicable entity pursuant to section 4192 of the Internal 

22 Revenue Code of 1986. 


kjohnson on DSK79L0C42 with BILLS
15 

•S 378 IS

1 SEC. 3. EXCISE TAX ON PRESCRIPTION DRUGS SUBJECT TO 

2 PRICE SPIKES. 

3 (a) IN GENERAL.—Subchapter E of chapter 32 of the 

4 Internal Revenue Code of 1986 is amended by adding at 

5 the end the following new section: 

6 ‘‘SEC. 4192. PRESCRIPTION DRUGS SUBJECT TO PRICE 

7 SPIKES. 

8 ‘‘(a) IMPOSITION OF TAX.— 

9 ‘‘(1) IN GENERAL.—Subject to paragraph (3), 

10 for each taxable prescription drug sold by an appli11 cable entity during the calendar year, there is hereby 

12 imposed on such entity a tax equal to the greater 

13 of— 

14 ‘‘(A) the annual price spike tax for such 

15 prescription drug, or 

16 ‘‘(B) subject to paragraph (2), the cumu17 lative price spike tax for such prescription drug. 

18 ‘‘(2) LIMITATION.—In the case of a taxable 

19 prescription drug for which the applicable period (as 

20 determined under subsection (c)(2)(E)(i)) is less 

21 than 2 calendar years, the cumulative price spike tax 

22 shall not apply. 

23 ‘‘(3) EXEMPTION.—For any calendar year in 

24 which the Secretary of Health and Human Services 

25 has provided an exemption for a taxable prescription 

26 drug pursuant to section 2(d) of the Stop Price 


kjohnson on DSK79L0C42 with BILLS
16 

•S 378 IS

1 Gouging Act, the amount of the tax determined 

2 under paragraph (1) for such drug or device for 

3 such calendar year shall be reduced to zero. 

4 ‘‘(b) ANNUAL PRICE SPIKE TAX.— 

5 ‘‘(1) IN GENERAL.—The amount of the annual 

6 price spike tax shall be equal to the applicable per7 centage of the price spike revenue received by the 

8 applicable entity on the sale of the taxable prescrip9 tion drug during the calendar year. 

10 ‘‘(2) APPLICABLE PERCENTAGE.—For purposes 

11 of paragraph (1), the applicable percentage shall be 

12 equal to— 

13 ‘‘(A) in the case of a taxable prescription 

14 drug which has been subject to a price spike 

15 percentage greater than the applicable price in16 crease allowance (as defined in section 

17 2(a)(6)(C) of the Stop Price Gouging Act) but 

18 less than 15 percent, 50 percent, 

19 ‘‘(B) in the case of a taxable prescription 

20 drug which has been subject to a price spike 

21 percentage equal to or greater than 15 percent 

22 but less than 20 percent, 75 percent, and 

23 ‘‘(C) in the case of a taxable prescription 

24 drug which has been subject to a price spike 


kjohnson on DSK79L0C42 with BILLS
17 

•S 378 IS

1 percentage equal to or greater than 20 percent, 

2 100 percent. 

3 ‘‘(c) CUMULATIVE PRICE SPIKE TAX.— 

4 ‘‘(1) IN GENERAL.—The amount of the cumu5 lative price spike tax shall be equal to the applicable 

6 percentage of the cumulative price spike revenue re7 ceived by the applicable entity on the sale of the tax8 able prescription drug during the calendar year. 

9 ‘‘(2) APPLICABLE PERCENTAGE.— 

10 ‘‘(A) IN GENERAL.—For purposes of para11 graph (1), the applicable percentage shall be 

12 equal to— 

13 ‘‘(i) in the case of a taxable prescrip14 tion drug which has been subject to a cu15 mulative price spike percentage greater 

16 than the cumulative price increase allow17 ance but less than the first multi-year per18 centage, 50 percent, 

19 ‘‘(ii) in the case of a taxable prescrip20 tion drug which has been subject to a cu21 mulative price spike percentage equal to or 

22 greater than the first multi-year percent23 age but less than the second multi-year 

24 percentage, 75 percent, and 


kjohnson on DSK79L0C42 with BILLS
18 

•S 378 IS

1 ‘‘(iii) in the case of a taxable prescrip2 tion drug which has been subject to a cu3 mulative price spike percentage equal to or 

4 greater than the second multi-year percent5 age, 100 percent. 

6 ‘‘(B) CUMULATIVE PRICE SPIKE PERCENT7 AGE.—The cumulative price spike percentage is 

8 the percentage (if any) by which— 

9 ‘‘(i) the average manufacturer price of 

10 the taxable prescription drug in commerce 

11 for the preceding calendar year, exceeds 

12 ‘‘(ii) the average manufacturer price 

13 of such prescription drug in commerce for 

14 the base year. 

15 ‘‘(C) CUMULATIVE PRICE INCREASE AL16 LOWANCE.—For purposes of clause (i) of sub17 paragraph (A), the cumulative price increase al18 lowance for any calendar year is the percentage 

19 (rounded to the nearest one-tenth of 1 percent) 

20 by which the C-CPI-U (as defined in section 

21 1(f)(6)) for that year exceeds the C-CPI-U for 

22 the base year. 

23 ‘‘(D) MULTI-YEAR PERCENTAGES.—For 

24 purposes of subparagraph (A), the first multi25 year percentage and second multi-year percentVerDate Sep 11 2014 03:17 Feb 16, 2019 Jkt 089200 PO 00000 Frm 00018 Fmt 6652 Sfmt 6201 E:\BILLS\S378.IS S378

kjohnson on DSK79L0C42 with BILLS
19 

•S 378 IS

1 age shall be determined in accordance with the 

2 following table: 

‘‘Number of years in applicable period 

First 

multi-year 

percentage 

Second 

multi-year 

percentage 

2 years .................................................................... 17.5 22.5

3 years .................................................................... 20.0 25.0

4 years .................................................................... 22.5 27.5

5 years .................................................................... 25.0 30.0. 

3 ‘‘(E) APPLICABLE PERIOD AND BASE

4 YEAR.— 

5 ‘‘(i) APPLICABLE PERIOD.—The appli6 cable period shall be the lesser of— 

7 ‘‘(I) the 5 preceding calendar 

8 years, 

9 ‘‘(II) all calendar years beginning 

10 after the date of enactment of this 

11 section, or 

12 ‘‘(III) all calendar years in which 

13 the taxable prescription drug was sold 

14 in commerce. 

15 ‘‘(ii) BASE YEAR.—The base year 

16 shall be the calendar year immediately pre17 ceding the applicable period. 

18 ‘‘(3) CUMULATIVE PRICE SPIKE REVENUE.— 

19 For purposes of paragraph (1), the cumulative price 

20 spike revenue for any taxable prescription drug shall 

21 be an amount equal to— 


kjohnson on DSK79L0C42 with BILLS
20 

•S 378 IS

1 ‘‘(A) an amount equal to the product of— 

2 ‘‘(i) an amount (not less than zero) 

3 equal to— 

4 ‘‘(I) the average manufacturer 

5 price of such prescription drug in 

6 commerce for the preceding calendar 

7 year, minus 

8 ‘‘(II) the average manufacturer 

9 price of such prescription drug in 

10 commerce for the base year, and 

11 ‘‘(ii) the total number of units of such 

12 prescription drug which were sold in com13 merce in the preceding calendar year, 

14 minus 

15 ‘‘(B) an amount equal to the sum of the 

16 adjustment amounts, if any, determined under 

17 section 2(a)(7)(C) of the Stop Price Gouging 

18 Act for each calendar year during the applicable 

19 period. 

20 ‘‘(d) DEFINITIONS.—For purposes of this section— 

21 ‘‘(1) TAXABLE PRESCRIPTION DRUG.—The 

22 term ‘taxable prescription drug’ means a prescrip23 tion drug (as defined in section 2(a)(5) of the Stop 

24 Price Gouging Act) which has been identified by the 

25 Inspector General of the Department of Health and 


kjohnson on DSK79L0C42 with BILLS
21 

•S 378 IS

1 Human Services, under section 2(c)(2)(A) of such 

2 Act, as being subject to a price spike. 

3 ‘‘(2) OTHER TERMS.—The terms ‘applicable en4 tity’, ‘average manufacturer price’, ‘price spike’, 

5 ‘price spike percentage’, and ‘price spike revenue’ 

6 have the same meaning given such terms under sec7 tion 2(a) of the Stop Price Gouging Act.’’. 

8 (b) CLERICAL AMENDMENTS.— 

9 (1) The heading of subchapter E of chapter 32 

10 of the Internal Revenue Code of 1986 is amended by 

11 striking ‘‘Medical Devices’’ and inserting ‘‘Cer12 tain Medical Devices and Prescription 

13 Drugs’’. 

14 (2) The table of subchapters for chapter 32 of 

15 such Code is amended by striking the item relating 

16 to subchapter E and inserting the following new 

17 item: 

‘‘SUBCHAPTER E. CERTAIN MEDICAL DEVICES AND PRESCRIPTION DRUGS’’. 

18 (3) The table of sections for subchapter E of 

19 chapter 32 of such Code is amended by adding at 

20 the end the following new item: 

‘‘Sec. 4192. Prescription drugs subject to price spikes.’’. 

21 (c) EFFECTIVE DATE.—The amendments made by 

22 this section shall apply to sales after the date of the enact23 ment of this Act. 


kjohnson on DSK79L0C42 with BILLS
22 

•S 378 IS

1 SEC. 4. STUDY ON MONOPOLY MEDICAL PRODUCTS. 

2 (a) IN GENERAL.—The Comptroller General of the 

3 United States shall conduct a study that examines— 

4 (1) how drug manufacturers and health plans 

5 (including private insurers, the Medicare program, 

6 and State Medicaid programs) establish initial 

7 launch prices for newly approved drugs; and 

8 (2) alternative methods that have been pro9 posed for setting the price of new drugs. 

10 (b) STUDY OF SPECIFIC DRUGS.—As part of the 

11 study described in subsection (a), the Comptroller General 

12 shall examine drug pricing with respect to several drugs 

13 approved within the 5-year period immediately preceding 

14 the date of enactment of this Act and explore potential 

15 alternative approaches to establish new drug prices that 

16 could help make new drugs more affordable, better reflect 

17 the clinical value of such drugs in treating patients, and 

18 maintain incentives for innovation. 

19 (c) FACTORS.—In conducting the study described in 

20 subsection (a), the Comptroller General shall consider— 

21 (1) what factors drug manufacturers and health 

22 plans consider in establishing initial launch prices; 

23 (2) how initial pricing decisions by drug manu24 facturers and health plans affect costs and use of 

25 services for patients and public programs such as 

26 the Medicare and Medicaid programs; 


kjohnson on DSK79L0C42 with BILLS
23 

•S 378 IS

1 (3) efforts by health plans to limit costs, includ2 ing through benefit design or coverage limitations; 

3 (4) how prices change in the first few years fol4 lowing a new drug’s launch; and 

5 (5) recommendations manufacturers, health 

6 plans, and other experts have for alternative ap7 proaches to establishing new drug prices and the 

8 benefits and challenges associated with such alter9 native approaches. 

10 SEC. 5. REVENUES COLLECTED. 

11 There are authorized to be appropriated to the Sec12 retary of Health and Human Services such sums as are 

13 equal to any increase in revenue to the Treasury by reason 

14 of the provisions of this Act or the amendments made by 

15 this Act for the purposes of increasing amounts available 

16 to the National Institutes of Health for research and de17 velopment of drugs. 

Æ 


kjohnson on DSK79L0C42 with BILLS